

## **Product datasheet for TR313399**

## 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com

OriGene Technologies, Inc.

nttps://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **DOC2A Human shRNA Plasmid Kit (Locus ID 8448)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** DOC2A Human shRNA Plasmid Kit (Locus ID 8448)

Locus ID: 8448
Synonyms: Doc2

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection:

Format:

Retroviral plasmids

Components: DOC2A - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

8448). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

RefSeq: NM 001282062, NM 001282063, NM 001282068, NM 003586, NR 104089, NR 104090,

NM 003586.1, NM 003586.2, NM 001282062.1, NM 001282063.1, NM 001282068.1,

BC055284, BC055284.1, BC041769, BC063436, NM 001282068.2, NM 003586.3

UniProt ID: Q14183

Summary: There are at least two protein isoforms of the Double C2 protein, namely alpha (DOC2A) and


beta (DOC2B), which contain two C2-like domains. DOC2A and DOC2B are encoded by different genes; these genes are at times confused with the unrelated DAB2 gene which was initially named DOC-2. DOC2A is mainly expressed in brain and is suggested to be involved in Ca(2+)-dependent neurotransmitter release. Alternative splicing results in multiple transcript

variants. [provided by RefSeq, Aug 2013]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our custom shRNA service.







## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).